/
/
Clinical Trial: Drug that Stops Myeloma Progression with Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Clinical Trial: Drug that Stops Myeloma Progression with Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma image
Clinical Trial: Drug that Stops Myeloma Progression with Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Posted Jun 26, 2017
TGF-β, a multifunctional cytokine, is produced in multiple myeloma cells and cells in the bone marrow environment and stimulates myeloma progression. A new drug called  TEW-797 targets this cytokine and kills myeloma cells alone and with other myeloma drugs.
“Our data demonstrate that TEW-7197 effectively modulates the MM TME and is associated with a potent anti-myeloma effect in an immunocompetent murine model of MM,” lead author Byung-gyu Kim, DVM, of Case Western Reserve University in Cleveland, Ohio, said during his presentation of the results of a study using this drug with ixazomib.
  TEW-7197 is now in a clinical trial with pomalidomide for relapse/refractory myeloma patients. The trial is open at two sites in Ohio. To learn more about this clinical trial, click here: Pomalidomide and TEW-7197 Clinical Trial
The author Allyse Shumway

about the author
Allyse Shumway

MyelomaCrowd Editorial Contributor. Daughter to a parent with cancer.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2021 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811